Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
-
Shares outstanding
-
266,212,950
-
Total 13F shares
-
45,661,103
-
Share change
-
-3,193,790
-
Total reported value
-
$190,513,250
-
Put/Call ratio
-
0%
-
Price per share
-
$4.17
-
Number of holders
-
60
-
Value change
-
-$17,791,387
-
Number of buys
-
24
-
Number of sells
-
39
Institutional Holders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) as of Q1 2022
As of 31 Mar 2022,
Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) was held by
60 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
45,661,103 shares.
The largest 10 holders included
Blackstone Inc., Nantahala Capital Management, LLC, Frazier Life Sciences Management, L.P., CITADEL ADVISORS LLC, TFG Asset Management GP Ltd, SCHRODER INVESTMENT MANAGEMENT GROUP, FMR LLC, Pendal Group Ltd, Capital World Investors, and JPMORGAN CHASE & CO.
This page lists
60
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.